Principal Investigator/s:         Professor Lorcan McGarvey

Name of the Study:             NOCION

Why is this Study important?

Chronic cough, defined as cough lasting more than 8 weeks, has been estimated to affect up to 10% of the adult population. Effective treatment options are highly desired as current treatments have variable and unreliably efficacy.

This study will assess the efficacy, safety, and tolerability of taplucainium inhalation powder (NOC-110) in adults with refractory or unexplained chronic cough.
 

What is the Research question/aim?  

The primary objective of the study is to evaluate the effects of Taplucainium Inhalation Powder on 24-hour cough frequency in Adults with Refractory or Unexplained Chronic Cough over the course of 28 days..

What the Study involves:

Following screening and an initial eligibility evaluation, this 13 week study will involve 7 clinical visits and 2 telephone consultations. 

Who can take part in the Study?

Adults aged 18yrs and over with refractory or unexplained chronic cough for ≥ 12 months.

Contact Information:

Sharon Carr, Lead Research Nurse

sharon.carr@belfasttrust.hscni.net

028095047647